Drugs / autologous TILs
autologous TILs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06488950 | Apr 2023 → Jun 2026 overdue | neoplasm | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03904537 | Feb → Dec 2019 | colorectal cancer | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous TILs | “Then, autologous TILs (0.1-1\*10\^10 cells) were transferred to participants via intravenous infusion.” NCT03904537 ↗ |
| Known as | anti-PD-1 antibody-activated TILs | “Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy” NCT03904537 ↗ |
| Known as | TILs | “Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy” NCT03904537 ↗ |
| Modality | Cell therapy | “autologous tumor-infiltrating lymphocytes (TILs)” NCT03904537 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT03904537 ↗ |